Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows

Immunotherapy struggles when tumours hide from the immune system. GRWD5769 solves this problem by making cancer cells (pink) visible to T-cells (white). Illustration: Nemes Laszlo/Alamy View image in fullscreen Immunotherapy struggles when tumours hide from the immune system. GRWD5769 solves this problem by making cancer cells (pink) visible to T-cells (white). Illustration: Nemes Laszlo/Alamy Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows Experimental tablet produces encouraging results in patients with world’s most common forms of disease ‘I was getting ready to say goodbye’: patient’s hope after smart drug success A smart drug that stops cancer cells “hiding” from treatment can shrink tumours by at least 30% in six of the world’s most common forms of the disease, early trial results show. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread. Researchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab. Researchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study. Crucially, immunotherapy had not worked or had stopped working. The smart drug was able to remove “invisibility cloaks” from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer. The findings were presented at the American Society of Clinical Oncology’s annual meeting in Chicago, the world’s largest cancer conference . GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients. Results from the phase 1 trial were presented at the conference by its principal investigator, Prof Fiona Thistlethwaite, a consultant medical oncologist and medical director of the Christie clinical research facility. Speaking to the Guardian in Chicago, Thistlethwaite said: “For a drug that is given as a tablet, this is very impressive. It’s early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform m